Dennis M. Lanfear - 06 Jun 2021 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
President & CEO, Director
Signature
/s/ McDavid Stilwell, as Attorney-in-Fact for Dennis M. Lanfear
Issuer symbol
CHRS
Transactions as of
06 Jun 2021
Net transactions value
-$283,246
Form type
4
Filing time
08 Jun 2021, 17:11:36 UTC
Next filing
23 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Options Exercise $125,040 +300,000 +155% $0.4168* 493,258 06 Jun 2021 Direct
transaction CHRS Common Stock Options Exercise $12,943 +31,054 +6.3% $0.4168* 524,312 08 Jun 2021 Direct
transaction CHRS Common Stock Sale $421,229 -31,054 -5.9% $13.56 493,258 08 Jun 2021 Direct F3
holding CHRS Common Stock 446,684 06 Jun 2021 By Trust F1
holding CHRS Common Stock 86,965 06 Jun 2021 By LLC F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 -300,000 -91% $0.000000 31,054 06 Jun 2021 Common Stock 300,000 $0.4168 Direct F4
transaction CHRS Stock Option (Right to Buy) Options Exercise $0 -31,054 -100% $0.000000* 0 08 Jun 2021 Common Stock 31,054 $0.4168 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee.
F2 These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President.
F3 The transaction was executed in multiple trades in prices ranging from $13.55 to $13.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
F4 The shares underlying this option are fully vested and exercisable as of the date hereof.